Osteoporosis medicines were linked to fewer repeat spinal fractures
A review examined medication outcomes in adults with an existing osteoporotic vertebral fracture, finding differences across drugs, comparisons, and follow-up periods.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
This abstract-based review associated several osteoporosis medicines with fewer subsequent vertebral fractures in adults who had already experienced one. Bisphosphonates had lower fracture odds than controls at the reported follow-ups, while teriparatide also compared favorably with bisphosphonates. These findings concern prevention after an existing fracture and do not establish a universally preferred medication.
The abstract does not describe control treatments, included study designs, or absolute fracture rates. Evidence for romosozumab was limited and concerned patients undergoing vertebral augmentation, restricting that result's applicability.
What researchers found
Subsequent vertebral fracture
Bisphosphonates versus control at 1 year: lower odds of another vertebral fracture. This odds ratio does not give the absolute probability of fracture.
Distinct outcomes
The review assessed new vertebral fractures alongside bone mineral density, pain, and disability measures. These outcomes answer different questions: a change in bone density or a symptom score should not be treated as a fracture prevented.
Comparisons need context
Teriparatide was associated with fewer subsequent vertebral fractures than controls and bisphosphonates. The romosozumab finding came from a procedural subgroup, so it cannot establish the same outcome for every adult with an osteoporotic fracture.
The original publication
Impact of anti-osteoporosis medication on refracture prevention following osteoporotic vertebral fracture: a systematic review and meta-analysis.
Jin H, Jin H, Suk KS et al.
Osteoporos Int · 2025
- PubMed ID
- 40846898
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.